Clinical Trial Update: The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma

View source ↗

Summary

A registry trial update for the LINFU U.S. Registry aiming to detect asymptomatic pancreatic ductal adenocarcinoma; enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma
• Pancreatic Intraepithelial Neoplasia

Snippet

Sponsor: Adenocyte, LLC | Conditions: Pancreatic Adenocarcinoma, Pancreatic Intraepithelial Neoplasia | Status: ENROLLING_BY_INVITATION